Marino Stram & Associates LLC Reduces Holdings in Pfizer Inc. (NYSE:PFE)

Marino Stram & Associates LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 13.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 56,183 shares of the biopharmaceutical company’s stock after selling 8,554 shares during the quarter. Marino Stram & Associates LLC’s holdings in Pfizer were worth $1,618,000 as of its most recent filing with the SEC.

A number of other large investors have also recently made changes to their positions in the stock. Worth Asset Management LLC bought a new position in shares of Pfizer in the first quarter worth approximately $29,000. Briaud Financial Planning Inc purchased a new position in shares of Pfizer during the 3rd quarter valued at $30,000. GoalVest Advisory LLC boosted its holdings in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares during the period. Mizuho Securities Co. Ltd. purchased a new stake in Pfizer in the 3rd quarter worth $34,000. Finally, VisionPoint Advisory Group LLC raised its holdings in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 1,047 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on PFE shares. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Finally, Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $36.88.

Pfizer Stock Down 0.4 %

Shares of PFE traded down $0.11 during midday trading on Tuesday, reaching $25.80. 13,327,945 shares of the stock were exchanged, compared to its average volume of 42,333,582. The company has a market capitalization of $146.09 billion, a P/E ratio of 71.69, a PEG ratio of 1.16 and a beta of 0.61. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. Pfizer Inc. has a 52 week low of $25.61 and a 52 week high of $41.33. The company’s 50 day moving average is $27.27 and its two-hundred day moving average is $28.84.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter last year, the firm posted $1.14 EPS. The company’s revenue for the quarter was down 41.3% on a year-over-year basis. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.